Literature DB >> 22282471

The nuclear receptor, Nor-1, markedly increases type II oxidative muscle fibers and resistance to fatigue.

Michael A Pearen1, Natalie A Eriksson, Rebecca L Fitzsimmons, Joel M Goode, Nick Martel, Sofianos Andrikopoulos, George E O Muscat.   

Abstract

Nuclear hormone receptors (NR) have been implicated as regulators of lipid and carbohydrate metabolism. The orphan NR4A subgroup has emerged as regulators of metabolic function. Targeted silencing of neuron-derived orphan receptor 1 (Nor-1)/NR4A3 in skeletal muscle cells suggested that this NR was necessary for oxidative metabolism in vitro. To investigate the in vivo role of Nor-1, we have developed a mouse model with preferential expression of activated Nor-1 in skeletal muscle. In skeletal muscle, this resulted in a marked increase in: 1) myoglobin expression, 2) mitochondrial DNA and density, 3) oxidative enzyme staining, and 4) genes/proteins encoding subunits of electron transport chain complexes. This was associated with significantly increased type IIA and IIX myosin heavy chain mRNA and proteins and decreased type IIB myosin heavy chain mRNA and protein. The contractile protein/fiber type remodeling driving the acquisition of the oxidative type II phenotype was associated with 1) the significantly increased expression of myocyte-specific enhancer factor 2C, and phospho-histone deacetylase 5, and 2) predominantly cytoplasmic HDAC5 staining in the Tg-Nor-1 mice. Moreover, the Nor-1 transgenic line displayed significant improvements in glucose tolerance, oxygen consumption, and running endurance (in the absence of increased insulin sensitivity), consistent with increased oxidative capacity of skeletal muscle. We conclude that skeletal muscle fiber type is not only regulated by exercise-sensitive calcineurin-induced signaling cascade but also by NR signaling pathways that operate at the nexus that coordinates muscle performance and metabolic capacity in this major mass tissue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282471      PMCID: PMC5417129          DOI: 10.1210/me.2011-1274

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  67 in total

1.  GAL4-VP16 is an unusually potent transcriptional activator.

Authors:  I Sadowski; J Ma; S Triezenberg; M Ptashne
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

2.  Thermogenesis in human skeletal muscle as measured by direct microcalorimetry and muscle contractile performance during beta-adrenoceptor blockade.

Authors:  B Fagher; H Liedholm; M Monti; U Moritz
Journal:  Clin Sci (Lond)       Date:  1986-05       Impact factor: 6.124

3.  Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily.

Authors:  Shinji Kagaya; Naganari Ohkura; Toshihiko Tsukada; Masami Miyagawa; Yuji Sugita; Gozoh Tsujimoto; Kenji Matsumoto; Hirohisa Saito; Ryoichi Hashida
Journal:  Biol Pharm Bull       Date:  2005-09       Impact factor: 2.233

4.  Evidence for Nr4a1 as a cold-induced effector of brown fat thermogenesis.

Authors:  Timo Kanzleiter; Tatjana Schneider; Isabel Walter; Florian Bolze; Christoph Eickhorst; Gerhard Heldmaier; Susanne Klaus; Martin Klingenspor
Journal:  Physiol Genomics       Date:  2005-10-11       Impact factor: 3.107

5.  TRAP220 is modulated by the antineoplastic agent 6-Mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors.

Authors:  K D Senali Abayratna Wansa; George E O Muscat
Journal:  J Mol Endocrinol       Date:  2005-06       Impact factor: 5.098

6.  The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine.

Authors:  K D Senali Abayratna Wansa; Jonathan M Harris; Grace Yan; Peter Ordentlich; George E O Muscat
Journal:  J Biol Chem       Date:  2003-04-22       Impact factor: 5.157

7.  Regulation of the nuclear hormone receptor nur77 in muscle: influence of exercise-activated pathways in vitro and obesity in vivo.

Authors:  Timo Kanzleiter; Donna Wilks; Elaine Preston; Jiming Ye; Georgia Frangioudakis; Gregory James Cooney
Journal:  Biochim Biophys Acta       Date:  2009-05-15

8.  Orphan nuclear receptor NOR-1 enhances 3',5'-cyclic adenosine 5'-monophosphate-dependent uncoupling protein-1 gene transcription.

Authors:  Naresh Kumar; Dianxin Liu; Haibo Wang; Jacques Robidoux; Sheila Collins
Journal:  Mol Endocrinol       Date:  2008-01-31

9.  Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter.

Authors:  Nigel J Pearce; Jonathan R S Arch; John C Clapham; Matthew P Coghlan; Stacey L Corcoran; Carolyn A Lister; Andrea Llano; Gary B Moore; Gregory J Murphy; Stephen A Smith; Colleen M Taylor; John W Yates; Alastair D Morrison; Alexander J Harper; Lynne Roxbee-Cox; Alejandro Abuin; Ed Wargent; Julie C Holder
Journal:  Metabolism       Date:  2004-10       Impact factor: 8.694

10.  Involvement of neuron-derived orphan receptor-1 (NOR-1) in LDL-induced mitogenic stimulus in vascular smooth muscle cells: role of CREB.

Authors:  Jordi Rius; José Martínez-González; Javier Crespo; Lina Badimon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-02-12       Impact factor: 8.311

View more
  35 in total

1.  Perm1 enhances mitochondrial biogenesis, oxidative capacity, and fatigue resistance in adult skeletal muscle.

Authors:  Yoshitake Cho; Bethany C Hazen; Paulo G Gandra; Samuel R Ward; Simon Schenk; Aaron P Russell; Anastasia Kralli
Journal:  FASEB J       Date:  2015-10-19       Impact factor: 5.191

2.  6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3.

Authors:  Qinglan Liu; Xiaolin Zhu; Lusheng Xu; Yuchang Fu; W Timothy Garvey
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-10       Impact factor: 4.310

Review 3.  Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit.

Authors:  Sean L McGee; Mark Hargreaves
Journal:  Nat Rev Endocrinol       Date:  2020-07-06       Impact factor: 43.330

4.  Creb coactivators direct anabolic responses and enhance performance of skeletal muscle.

Authors:  Nelson E Bruno; Kimberly A Kelly; Richard Hawkins; Mariam Bramah-Lawani; Antonio L Amelio; Jerome C Nwachukwu; Kendall W Nettles; Michael D Conkright
Journal:  EMBO J       Date:  2014-03-27       Impact factor: 11.598

5.  The orphan nuclear receptor Nor1/Nr4a3 is a negative regulator of β-cell mass.

Authors:  Anne-Françoise Close; Nidheesh Dadheech; Bárbara Scoralick Villela; Claude Rouillard; Jean Buteau
Journal:  J Biol Chem       Date:  2019-01-29       Impact factor: 5.157

6.  Divergent skeletal muscle respiratory capacities in rats artificially selected for high and low running ability: a role for Nor1?

Authors:  Erin J Stephenson; Nigel K Stepto; Lauren G Koch; Steven L Britton; John A Hawley
Journal:  J Appl Physiol (1985)       Date:  2012-08-30

Review 7.  Control of Muscle Metabolism by the Mediator Complex.

Authors:  Leonela Amoasii; Eric N Olson; Rhonda Bassel-Duby
Journal:  Cold Spring Harb Perspect Med       Date:  2018-02-01       Impact factor: 6.915

8.  Nuclear receptor 4A (NR4A) family - orphans no more.

Authors:  Stephen Safe; Un-Ho Jin; Benjamin Morpurgo; Ala Abudayyeh; Mandip Singh; Ronald B Tjalkens
Journal:  J Steroid Biochem Mol Biol       Date:  2015-04-23       Impact factor: 4.292

9.  The Nuclear Receptor, Nor-1, Induces the Physiological Responses Associated With Exercise.

Authors:  Joel M Goode; Michael A Pearen; Zewen K Tuong; Shu-Ching M Wang; Tae Gyu Oh; Emily X Shao; George E O Muscat
Journal:  Mol Endocrinol       Date:  2016-05-04

10.  Transgenic muscle-specific Nor-1 expression regulates multiple pathways that effect adiposity, metabolism, and endurance.

Authors:  Michael A Pearen; Joel M Goode; Rebecca L Fitzsimmons; Natalie A Eriksson; Gethin P Thomas; Gary J Cowin; S-C Mary Wang; Zewen K Tuong; George E O Muscat
Journal:  Mol Endocrinol       Date:  2013-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.